We aspire for the utilization of PD-1/PD-L1 inhibitors to assume a pivotal role in the adjuvant therapy of high-risk melanoma (newly diagnosed), thereby furnishing surgeons with precise treatment strategies through pertinent clinical investigations. This evidence concerns the gene CD274 and melanoma.